CJC-1295 NO DAC - Mod GRF (1-29) - 5mg

SPECIFICATIONS

Product Code: CJND05

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Molecular Formula: C152H252N44O42

Molecular Weight: 3367.9 g/mol

CAS: 863288-34-0

Purity: Technical / Research Grade 98%

Other details: No TFA Salt

Form: Lyophilized powder

Color: White

Storage temperature: -20°C

Source: Synthetic

Safety classification: Standard handling

DESCRIPTION

CJC-1295 without DAC, also referred to as Modified GRF (1-29), is a synthetic peptide derived from the first 29 amino acids of growth hormone–releasing hormone (GHRH). It is structurally related to Sermorelin, representing a chemically optimized variant designed to improve stability while preserving GHRH-associated signaling characteristics.

Structural characteristics and peptide optimization (preclinical)

Native GRF (1-29) exhibits a very short biological persistence, which has limited its experimental utility. As a result, Modified GRF (1-29) was developed through targeted amino acid substitutions to reduce enzymatic degradation and allow more controlled investigation of short-acting GHRH signaling dynamics in laboratory settings.

Despite these modifications, Modified GRF (1-29) retains a relatively short activity profile, which has been leveraged in preclinical research to study physiological-like pulsatile activation of the growth hormone axis under experimental conditions.

GHRH signaling and GH–IGF axis research (preclinical)

In in vitro systems and animal studies, CJC-1295 without DAC has been used to investigate GHRH-mediated endocrine signaling, particularly pathways associated with growth hormone release and downstream insulin-like growth factor (IGF)–related biochemical cascades.

These experimental systems have explored how short-duration GHRH analogues influence:

• transient GH signaling patterns
• protein synthesis–associated pathways
• lipid metabolism–related biochemical markers
• bone and connective tissue–related signaling
• cellular repair and turnover mechanisms

All observations are interpreted as pathway-level effects, not functional or clinical outcomes.

Comparison with DAC-modified CJC-1295 (preclinical)

CJC-1295 without DAC differs from CJC-1295-DAC primarily in its pharmacokinetic behavior. While both peptides interact with GHRH receptors, the DAC-modified version has been engineered to bind serum albumin, resulting in extended circulating persistence.

By contrast, Modified GRF (1-29) has been utilized in research contexts where short-acting, pulsatile signaling is preferred, allowing investigators to examine temporal patterns of GH–IGF axis activation without prolonged receptor engagement.

Comparative preclinical studies have used these two formats to explore differences between:

• short-pulse versus sustained GHRH stimulation
• transient versus prolonged endocrine signaling
• physiological-mimetic versus extended-exposure response profiles

Combination peptide research (preclinical)

In experimental settings, Modified GRF (1-29) has also been included in combination studies with other GH-related peptides to investigate coordinated signaling within the endocrine network. These studies focus on mechanistic interactions and signal integration, without implying optimized protocols or functional outcomes.

REFERENCES

All information presented above is derived from in vitro experiments, animal studies, and other preclinical research models. These data are intended solely for basic scientific investigation of biological mechanisms and do not imply any therapeutic, diagnostic, preventive, or clinical use in humans or animals.    

A. Volpe et al., "Clinical use of growth hormone-releasing factor for induction of superovulation" [PubMed]

M. Ionescu et al., "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog" [PubMed]

S.L. Teichman et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" [PubMed]

M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse" [PubMed]

M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse" [American Journal of Physiology-Endocrinology and Metabolism]

L. Sackmann-Sala et al., "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects" [PubMed]

DISCLAIMER

This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.